Immune checkpoint blockade (ICB) therapies, such as monoclonal antibodies against PD-1, PD-L1, or CTLA-4, prolong the survival of a subset of patients with melanoma, non-small cell lung cancer, or renal-cell cancer, among other cancer types8–10. This evidence concerns the gene CD274 and cancer.